Press Releases

Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer

Exceeding Anticipated Timelines with Accelerated Momentum

• Interim Data Analysis Anticipated in Mid-2024
• Expects Full Enrollment by Q1 2025

Panbela Announces Publication of Clinical Data: A New Approaches to Neuroblastoma Therapy Trial

Panbela Announces Publication of Clinical Data Titled:

Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

• A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma.

Panbela Announces 1-for-20 Reverse Stock Split Effective 1/18/24

Panbela Announces Exercise of Warrants, Issuance of New Warrants in Private Placement for $2M Gross Proceeds Priced At-the-Market

Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma

Panbela Announces Publication of Abstract: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors

Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification

Panbela Provides Business Update and Reports Q3 2023 Financial Results

Panbela Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9M Gross Proceeds Priced At-the-Market

Panbela Announces Publication of Preclinical and Clinical Data: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes

A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.